Donidalorsen may improve quality of life for people with HAE
Donidalorsen, a preventive therapy being developed to reduce the frequency of swelling attacks for people with hereditary angioedema (HAE), significantly improved quality of life and symptom control for people with the condition, a new analysis of clinical trial data suggests. Ionis Pharmaceuticals, donidalorsen’s developer, funded the study,…